Aravind Basavapathruni

1.8k total citations · 1 hit paper
25 papers, 1.4k citations indexed

About

Aravind Basavapathruni is a scholar working on Infectious Diseases, Virology and Molecular Biology. According to data from OpenAlex, Aravind Basavapathruni has authored 25 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Infectious Diseases, 14 papers in Virology and 9 papers in Molecular Biology. Recurrent topics in Aravind Basavapathruni's work include HIV/AIDS drug development and treatment (15 papers), HIV Research and Treatment (14 papers) and Epigenetics and DNA Methylation (6 papers). Aravind Basavapathruni is often cited by papers focused on HIV/AIDS drug development and treatment (15 papers), HIV Research and Treatment (14 papers) and Epigenetics and DNA Methylation (6 papers). Aravind Basavapathruni collaborates with scholars based in United States, South Africa and Israel. Aravind Basavapathruni's co-authors include Karen S. Anderson, Margaret Porter Scott, Mikel P. Moyer, Edward J. Olhava, Scott R. Daigle, Robert A. Copeland, Roy M. Pollock, Richard Chesworth, Victoria M. Richon and Lei Jin and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Biochemistry.

In The Last Decade

Aravind Basavapathruni

25 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia

2013 546 citations Scott R. Daigle, Edward J. Olhava et al. Blood profile →

Peers

Countries citing papers authored by Aravind Basavapathruni

Since Specialization

Citations

This map shows the geographic impact of Aravind Basavapathruni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aravind Basavapathruni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aravind Basavapathruni more than expected).

Fields of papers citing papers by Aravind Basavapathruni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aravind Basavapathruni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aravind Basavapathruni. The network helps show where Aravind Basavapathruni may publish in the future.

Co-authorship network of co-authors of Aravind Basavapathruni

This figure shows the co-authorship network connecting the top 25 collaborators of Aravind Basavapathruni. A scholar is included among the top collaborators of Aravind Basavapathruni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aravind Basavapathruni. Aravind Basavapathruni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract PR10: IK-595, a MEK-RAF complex inhibitor, obviates CRAF mediated resistance resulting in superior RAS/MAPK pathway inhibition and anti-tumor activity in RAS/RAF altered cancers 2023 ·Molecular Cancer Research ·Eric Haines, Michael Burke, (unknown), Víctor R. De Jesús, Bin Li, Joseph Manna, George A. Punkosdy, Oksana Zavidij, Sarah R. Wessel, (unknown), Jill Cavanaugh, (unknown), Aravind Basavapathruni, Lan Xu, Sergio Santillana, (unknown), (unknown)	1
2	Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target 2015 ·Journal of Controlled Release ·Nigel J. Waters, Scott R. Daigle, (unknown), Aravind Basavapathruni, Carly Campbell, (unknown), (unknown), Edward J. Olhava, Roy M. Pollock, (unknown), (unknown)	21
3	Nonclinical pharmacokinetics and metabolism of EPZ‐5676, a novel DOT1L histone methyltransferase inhibitor 2014 ·Biopharmaceutics & Drug Disposition ·Aravind Basavapathruni, Edward J. Olhava, Scott R. Daigle, (unknown), Lei Jin, P. Ann Boriack‐Sjodin, Christina J. Allain, Christine R. Klaus, Alejandra Raimondi, Margaret Porter Scott, (unknown), Victoria M. Richon, Roy M. Pollock, Robert A. Copeland, Mikel P. Moyer, Richard Chesworth, Paul G. Pearson, Nigel J. Waters	64
4	Potent inhibition of DOT1L as treatment of MLL-fusion leukemia breakdown → 2013 ·Blood ·Scott R. Daigle, Edward J. Olhava, (unknown), Aravind Basavapathruni, Lei Jin, P. Ann Boriack‐Sjodin, Christina J. Allain, Christine R. Klaus, Alejandra Raimondi, Margaret Porter Scott, Nigel J. Waters, Richard Chesworth, Mikel P. Moyer, Robert A. Copeland, Victoria M. Richon, Roy M. Pollock	546
5	Bifunctional inhibition of HIV-1 reverse transcriptase: A first step in designing a bifunctional triphosphate 2012 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Aravind Basavapathruni, (unknown), Guangxiu Dai, Wolfgang Hinz, Adrian S. Ray, Eisuke Murakami, Joy Y. Feng, Fei You, Ginger E. Dutschman, David J. Austin, Kathlyn A. Parker, Karen S. Anderson	6
6	Conformational Adaptation Drives Potent, Selective and Durable Inhibition of the Human Protein Methyltransferase DOT1L 2012 ·Chemical Biology & Drug Design ·Aravind Basavapathruni, Lei Jin, Scott R. Daigle, Christina R. Majer, (unknown), Tim J. Wigle, Kevin W. Kuntz, Richard Chesworth, Roy M. Pollock, Margaret Porter Scott, Mikel P. Moyer, Victoria M. Richon, Robert A. Copeland, Edward J. Olhava	114
7	Preclinical Characterization of a Potent, Selective Inhibitor of the Protein Methyltransferase DOT1L for Use in the Treatment of MLL-Rearranged Leukemia. 2012 ·Blood ·Roy M. Pollock, Scott R. Daigle, (unknown), Aravind Basavapathruni, Lei Jin, Christina J. Allain, Christine R. Klaus, Alejandra Raimondi, Margaret Porter Scott, Richard Chesworth, Mikel P. Moyer, Robert A. Copeland, Victoria M. Richon, Edward J. Olhava	3
8	Envelope Variable Region 4 Is the First Target of Neutralizing Antibodies in Early Simian Immunodeficiency Virus mac251 Infection of Rhesus Monkeys 2012 ·Journal of Virology ·Wendy W. Yeh, (unknown), Caroline A. Miller, Aravind Basavapathruni, Jinrong Zhang, Srinivas S. Rao, Gary J. Nabel, John R. Mascola, Norman L. Letvin, Michael S. Seaman	6
9	Impact of enzyme concentration and residence time on apparent activity recovery in jump dilution analysis 2011 ·Analytical Biochemistry ·Robert A. Copeland, Aravind Basavapathruni, Mikel P. Moyer, Margaret Porter Scott	82
10	Envelope Vaccination Shapes Viral Envelope Evolution following Simian Immunodeficiency Virus Infection in Rhesus Monkeys 2009 ·Journal of Virology ·Aravind Basavapathruni, Wendy W. Yeh, Rory Coffey, James B. Whitney, Peter Hraber, (unknown), Bette Korber, Srinivas S. Rao, Gary J. Nabel, John R. Mascola, Michael S. Seaman, Norman L. Letvin	8
11	C-2-Aryl O-substituted HI-236 derivatives as non-nucleoside HIV-1 reverse-transcriptase inhibitors 2008 ·Bioorganic & Medicinal Chemistry ·Roger Hunter, Yassir Younis, (unknown), (unknown), Kevin J. Naidoo, Melissa A. Petersen, Christopher M. Bailey, Aravind Basavapathruni, Karen S. Anderson	18
12	Reverse transcription of the HIV‐1 pandemic 2007 ·The FASEB Journal ·Aravind Basavapathruni, Karen S. Anderson	38
13	Mechanism of Action of (-)-(2R,4R)-1-(2-hydroxymethyl-1,3-dioxolan-4-yl)thymine as an anti-HIV agent 2007 ·Antiviral chemistry & chemotherapy ·Eisuke Murakami, Haiying Bao, Aravind Basavapathruni, Christopher M. Bailey, Jinfa Du, Holly M. Micolochick Steuer, Congrong Niu, Tony Whitaker, Karen S. Anderson, Michaël Otto, Phillip A. Furman	4
14	Developing Novel Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors: Beyond the Butterfly 2006 ·Current Pharmaceutical Design ·Karen S. Anderson, Aravind Basavapathruni	13
15	Optimization of diarylamines as non-nucleoside inhibitors of HIV-1 reverse transcriptase 2005 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Aravind Basavapathruni, Joseph T. Kim, Christopher M. Bailey, Ligong Wang, Karen S. Anderson, Andrew D. Hamilton, William L. Jorgensen	38
16	Mechanism of action of a novel viral mutagenic covert nucleotide: molecular interactions with HIV-1 reverse transcriptase and host cell DNA polymerases 2005 ·Antiviral Research ·E Murakami, Aravind Basavapathruni, W. E. C. Bradley, Kenneth C. Anderson	27
17	Computer-aided design of non-nucleoside inhibitors of HIV-1 reverse transcriptase 2005 ·Bioorganic & Medicinal Chemistry Letters ·William L. Jorgensen, (unknown), Julian Tirado‐Rives, Aravind Basavapathruni, Karen S. Anderson, Andrew D. Hamilton	104
18	Defining a Molecular Mechanism of Synergy between Nucleoside and Nonnucleoside AIDS Drugs 2004 ·Journal of Biological Chemistry ·Aravind Basavapathruni, Christopher M. Bailey, Karen S. Anderson	41
19	Probing the Molecular Mechanisms of AZT Drug Resistance Mediated by HIV-1 Reverse Transcriptase Using a Transient Kinetic Analysis 2003 ·Biochemistry ·Adrian S. Ray, Eisuke Murakami, Aravind Basavapathruni, (unknown), (unknown), Chung K. Chu, Raymond F. Schinazi, Karen S. Anderson	63
20	Mechanistic Studies to Understand the Progressive Development of Resistance in Human Immunodeficiency Virus Type 1 Reverse Transcriptase to Abacavir 2002 ·Journal of Biological Chemistry ·Adrian S. Ray, Aravind Basavapathruni, Karen S. Anderson	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact